Sail Biomedicines valuation, funding and investors
Sail Biomedicines works in RNA medicine design and engineering, based in Cambridge, United States. Founded in 2023, it has about 108 employees.
- Last round
- Growth · $465M · Jul 2026
- Valuation at last round
- $5.17B · implied
- Headcount
- 108 · flat
- Grade
- B
- Founded
- 2023
Sail Biomedicines valuation today
VCMC values Sail Biomedicines at $5.2B today, with a range of $3.4B to $8.1B and a grade of B. The valuation starts from its last funding round, a growth round in Jul 2026.
Valuation by date (48 rows)
Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.
| Date | Valuation | Range | Predicted in 1 yr | Phase | Headcount | Trend | Grade | Winding-down probability |
|---|---|---|---|---|---|---|---|---|
| 1 Jan 2023 | $20.8M | $7.56M – $57.0M | $22.7M (+9%) | before first round | – | unknown | D | 0% |
| 1 Feb 2023 | $20.9M | $7.62M – $57.5M | $22.8M (+9%) | before first round | – | unknown | D | 0% |
| 1 Mar 2023 | $21.1M | $7.67M – $57.9M | $23.0M (+9%) | before first round | – | unknown | D | 0% |
| 1 Apr 2023 | $21.2M | $7.73M – $58.3M | $23.2M (+9%) | before first round | – | unknown | D | 0% |
| 1 May 2023 | $21.4M | $7.78M – $58.7M | $23.3M (+9%) | before first round | – | unknown | D | 0% |
| 1 Jun 2023 | $21.5M | $7.84M – $59.2M | $23.5M (+9%) | before first round | – | unknown | D | 0% |
| 1 Jul 2023 | $21.7M | $7.90M – $59.6M | $23.7M (+9%) | before first round | – | unknown | D | 0% |
| 1 Aug 2023 | $21.9M | $7.96M – $60.0M | $23.7M (+8%) | before first round | – | unknown | D | 0% |
| 1 Sep 2023 | $22.0M | $8.02M – $60.5M | $23.7M (+8%) | before first round | – | unknown | D | 0% |
| 1 Oct 2023 | $22.2M | $8.07M – $60.9M | $23.7M (+7%) | before first round | – | unknown | D | 0% |
| 1 Nov 2023 | $22.3M | $8.13M – $61.4M | $23.7M (+6%) | before first round | – | unknown | D | 0% |
| 1 Dec 2023 | $22.5M | $8.19M – $61.8M | $23.7M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jan 2024 | $22.7M | $8.26M – $62.3M | $23.7M (+5%) | before first round | – | unknown | D | 0% |
| 1 Feb 2024 | $22.8M | $8.32M – $62.8M | $23.7M (+4%) | before first round | – | unknown | D | 0% |
| 1 Mar 2024 | $23.0M | $8.38M – $63.2M | $23.7M (+3%) | before first round | – | unknown | D | 0% |
| 1 Apr 2024 | $31.6M | $11.5M – $86.9M | $32.3M (+2%) | before first round | 110 | unknown | D | 0% |
| 1 May 2024 | $31.8M | $11.6M – $87.5M | $32.3M (+1%) | before first round | 110 | unknown | D | 0% |
| 1 Jun 2024 | $32.1M | $11.7M – $88.1M | $32.3M (+1%) | before first round | 110 | unknown | D | 0% |
| 1 Jul 2024 | $32.3M | $11.8M – $88.8M | $32.3M (0%) | before first round | 110 | unknown | D | 0% |
| 1 Aug 2024 | $32.3M | $11.8M – $88.8M | $32.3M (0%) | before first round | 110 | unknown | D | 0% |
| 1 Sep 2024 | $32.3M | $11.8M – $88.8M | $32.3M (0%) | before first round | 110 | unknown | D | 0% |
| 1 Oct 2024 | $32.3M | $11.8M – $88.8M | $32.3M (0%) | before first round | 110 | unknown | D | 0% |
| 1 Nov 2024 | $32.3M | $11.8M – $88.8M | $32.3M (0%) | before first round | 110 | unknown | D | 0% |
| 1 Dec 2024 | $32.3M | $11.8M – $88.8M | $32.3M (0%) | before first round | 110 | unknown | D | 0% |
| 1 Jan 2025 | $32.3M | $11.8M – $88.8M | $32.3M (0%) | before first round | 110 | unknown | D | 0% |
| 1 Feb 2025 | $32.3M | $11.8M – $88.8M | $32.3M (0%) | before first round | 110 | unknown | D | 0% |
| 1 Mar 2025 | $32.3M | $11.8M – $88.8M | $32.3M (0%) | before first round | 110 | unknown | D | 0% |
| 1 Apr 2025 | $32.3M | $11.8M – $88.8M | $32.3M (0%) | before first round | 110 | unknown | D | 0% |
| 1 May 2025 | $32.3M | $11.8M – $88.8M | $32.3M (0%) | before first round | 110 | unknown | D | 0% |
| 1 Jun 2025 | $32.3M | $11.8M – $88.8M | $32.3M (0%) | before first round | 110 | unknown | D | 0% |
| 1 Jul 2025 | $32.3M | $11.8M – $88.8M | $32.3M (0%) | before first round | 110 | unknown | D | 0% |
| 1 Aug 2025 | $32.3M | $11.8M – $88.8M | $32.3M (0%) | before first round | 110 | unknown | D | 0% |
| 1 Sep 2025 | $32.7M | $11.9M – $89.8M | $32.7M (0%) | before first round | 118 | flat | D | 0% |
| 1 Oct 2025 | $32.7M | $11.9M – $89.8M | $32.7M (0%) | before first round | 118 | unknown | D | 0% |
| 1 Nov 2025 | $32.7M | $11.9M – $89.8M | $32.7M (0%) | before first round | 118 | unknown | D | 0% |
| 1 Dec 2025 | $32.7M | $11.9M – $89.8M | $32.7M (0%) | before first round | 118 | unknown | D | 0% |
| 1 Jan 2026 | $32.7M | $11.9M – $89.8M | $32.7M (0%) | before first round | 118 | unknown | D | 0% |
| 1 Feb 2026 | $32.7M | $11.9M – $89.8M | $32.7M (0%) | before first round | 118 | unknown | D | 0% |
| 1 Mar 2026 | $26.2M | $11.7M – $79.6M | $26.2M (0%) | before first round | 105 | down | C | 58% |
| 1 Apr 2026 | $26.2M | $11.7M – $79.6M | $26.2M (0%) | before first round | 105 | down | C | 58% |
| 1 May 2026 | $26.2M | $11.7M – $79.6M | $26.2M (0%) | before first round | 105 | down | C | 58% |
| 1 Jun 2026 | $26.0M | $11.6M – $79.1M | $26.0M (0%) | before first round | 101 | down | C | 79% |
| 1 Jul 2026 | $26.0M | $11.6M – $79.1M | $26.0M (0%) | before first round | 101 | down | C | 79% |
| 30 Jul 2026 | $5.2B | $3.4B – $8.0B | $5.3B (+2%) | after a round | 101 | down | B | 79% |
| 1 Aug 2026 | $5.2B | $3.4B – $8.0B | $5.3B (+2%) | after a round | 101 | down | B | 79% |
| 1 Sep 2026 | $5.2B | $3.4B – $8.0B | $5.1B (-1%) | after a round | 101 | down | B | 79% |
| 1 Oct 2026 | $5.2B | $3.4B – $8.1B | $5.1B (-2%) | after a round | 108 | flat | B | 73% |
| 24 Oct 2026 | $5.2B | $3.4B – $8.1B | $5.0B (-3%) | after a round | 108 | flat | B | 67% |
Key facts about Sail Biomedicines
- Founded
- 2023
- Headquarters
- Cambridge, United States
- Employees
- about 108 -8% in a year
- Total raised
- $465M
- Funding rounds
- 1
- Last round
- Growth Equity Jul 2026
Sail Biomedicines funding history
Sail Biomedicines has 1 funding round on record, from Jul 2026 to Jul 2026, $465M in total. None disclosed a valuation.
Growth Equity 29 Jul 2026
With Johnson & Johnson.
Sources: sail.bio, goodwinlaw.com, bioxconomy.com and 2 more
$465M
Sail Biomedicines investors
1 investor has backed Sail Biomedicines.
- Johnson & Johnson
What Sail Biomedicines does
Sail Biomedicines works in pharmaceutical products, with 14 recorded offerings and customers in healthcare, biotechnology and pharmaceuticals.
Sail Biomedicines, Inc. is an American biotechnology company engaged in the development of programmable medicines, with a focus on RNA medicines. The company utilizes proprietary circular RNA technology and targeted nanoparticles for extra-hepatic delivery and scalable manufacturing, and employs generative AI technologies to accelerate the design of RNA medicines. Sail Biomedicines serves a range of therapeutic areas, including autoimmune, metabolic, infectious, and rare diseases, and is publicly traded on NASDAQ.
Description from Veridion's company data.
Products and services
- RNA Medicine Design and Engineering
- Circular RNA Technology Application
- Targeted Nanoparticle Formulation and Manufacturing
- Disease-Specific Therapeutic Development
- Chronic Disease Therapeutic Development
- Autoimmune Disease Therapeutic Development
- Metabolic Disease Therapeutic Development
- Infectious Disease Therapeutic Development
- Rare Disease Therapeutic Development
- Generative AI Platform Development
- Biomedical Prototyping and Iterative Learning
- Extra-Hepatic Therapeutic Delivery Solutions
- Scalable RNA Medicine Manufacturing
- Therapeutic Product Candidate Advancement
Markets
- Healthcare
- Biotechnology
- Pharmaceuticals
Technology
- Generative AI for RNA Medicine Design
- Circular RNA Technology
- Targeted Nanoparticle Formulation for Extra-Hepatic Delivery
- Disease-Specific Targeting Ligand Engineering
Business model
- Manufacturing
Industry codes (NAICS)
- 541714 Research and Development in Biotechnology (except Nanobiotechnology) 100% match
Questions about Sail Biomedicines
What is Sail Biomedicines worth?
Valuation $5.2B (range $3.4B to $8.1B), as of 24 Oct 2026.
Has Sail Biomedicines raised money?
Sail Biomedicines has 1 funding round on record, from Jul 2026 to Jul 2026, $465M in total. None disclosed a valuation.
Who has invested in Sail Biomedicines?
Johnson & Johnson.
How many people work at Sail Biomedicines?
About 108, down 8% over the last year. Headcount held at about 108 from Mar 2024 to Sep 2026.
What does Sail Biomedicines do?
Sail Biomedicines works in pharmaceutical products, with 14 recorded offerings and customers in healthcare, biotechnology and pharmaceuticals. Its main offerings are RNA medicine design and engineering, circular RNA technology application and targeted nanoparticle formulation and manufacturing.
When was Sail Biomedicines founded, and where is it based?
Sail Biomedicines was founded in 2023 and is based in Cambridge, United States. It has about 108 employees, down 8% over the last year.